Clinical Study to Evaluate the Possible Efficacy of Metformin in Patients With Parkinson's Disease

• Status: Not yet recruiting
• Trial end date: 2025-03-20
• Target enrollment: 0
• Participant gender: All

Summary

Parkinson's disease (PD) is one of the most common neurodegenerative diseases characterized by the progressive loss of dopaminergic (DA) neurons in the substantia nigra compacta (SNc) and aggregation of Lewy bodies in neurons. Although aging, oxidative damage and neuroinflammation have been recognized to play crucial roles in the pathogenesis of PD, the precise etiology remains obscure. Emerging evidence suggests PD is a systemic metabolic disease, and metabolic abnormality correlates with functional alternations in PD

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tanta University
• Collaborators: Eman Ibrahim Elberri, Faculty of Pharmacy, Tanta University; Fedaa Abd El-monem Kamal El-deen Kotkata Faculty of Pharmacy, Tanta University; Manal Ali Mahrous Hamouda Faculty of Pharmacy, Menufia University
• Treatments: Carbidopa; Carbidopa, levodopa drug combination; Levodopa; Metformin

Criteria

Inclusion Criteria:

Age ≥ 18 years Both males and females will be included Negative pregnancy test and effective contraception. Diagnosed Parkinson's disease patient taking Levodopa

Exclusion Criteria:

Secondary causes of parkinsonism Diabetic patients Patients taking anti-inflammatory drugs Atypical parkinsonian syndromes Prior stereotaxic surgery for Parkinson's disease Pregnancy and lactation Suffering from active malignancy Addiction to alcohol and/or drugs Known allergy to the studied medications